Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C42H64N2.2C16H18N2O5S |
| Molecular Weight | 1297.75 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 12 / 12 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC1(C)S[C@@H]2[C@H](NC(=O)COC3=CC=CC=C3)C(=O)N2[C@H]1C(O)=O.CC4(C)S[C@@H]5[C@H](NC(=O)COC6=CC=CC=C6)C(=O)N5[C@H]4C(O)=O.CC(C)C7=CC=C8C(CC[C@H]9[C@](C)(CNCCNC[C@]%10(C)CCC[C@@]%11(C)[C@H]%10CCC%12=C%11C=CC(=C%12)C(C)C)CCC[C@]89C)=C7
InChI
InChIKey=IJXFBPWHGGIUAV-YQUITFMISA-N
InChI=1S/C42H64N2.2C16H18N2O5S/c1-29(2)31-11-15-35-33(25-31)13-17-37-39(5,19-9-21-41(35,37)7)27-43-23-24-44-28-40(6)20-10-22-42(8)36-16-12-32(30(3)4)26-34(36)14-18-38(40)42;2*1-16(2)12(15(21)22)18-13(20)11(14(18)24-16)17-10(19)8-23-9-6-4-3-5-7-9/h11-12,15-16,25-26,29-30,37-38,43-44H,9-10,13-14,17-24,27-28H2,1-8H3;2*3-7,11-12,14H,8H2,1-2H3,(H,17,19)(H,21,22)/t37-,38-,39-,40-,41+,42+;2*11-,12+,14-/m011/s1
| Molecular Formula | C16H18N2O5S |
| Molecular Weight | 350.39 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C42H64N2 |
| Molecular Weight | 596.971 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
PENICILLIN V HYDRABAMINE, a semi-synthetic antibiotic, is used for the treatment of mild to moderately severe infections (e.g. dental infection, infections in the heart, middle ear infections, rheumatic fever, scarlet fever, skin infections, upper and lower respiratory tract infections) caused by susceptible, usually gram-positive, organisms.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.73 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/809408/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
8.23 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/809408/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/809408/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
20% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/809408/ |
500 mg single, oral dose: 500 mg route of administration: Oral experiment type: SINGLE co-administered: |
PENICILLIN V plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: FASTED |
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:57:55 GMT 2025
by
admin
on
Mon Mar 31 17:57:55 GMT 2025
|
| Record UNII |
8T7T79P87L
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
23724984
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY | |||
|
m387
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
6591-72-6
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY | |||
|
8T7T79P87L
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY | |||
|
C175188
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY | |||
|
100000085295
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY | |||
|
SUB03765MIG
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY | |||
|
52173
Created by
admin on Mon Mar 31 17:57:55 GMT 2025 , Edited by admin on Mon Mar 31 17:57:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |